Authors : Ayan Sarkar; Anusuya Nandi; Diptendra Bhattacharya

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/mwmk59nu

Scribd : https://tinyurl.com/y46k2wz4

DOI : https://doi.org/10.38124/ijisrt/26May2014

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Cancer, a worldwide major cause of mortality, treated with conventional treatments often exhibits limited efficacy and significant side effects. Nanotechnology has been recognized as a viable area for improving cancer treatment recently. The special properties of nanoparticles and their ability to interact with biological systems at the nanoscale have paved the way for targeted cancer therapy, enabling precision medicine approaches. This abstract presents an outline of the use of nanotechnology in targeted cancer therapy. First, it highlights the drawbacks of conventional cancer therapies that includes chemotherapy and radiation therapies, which often lack specificity and result in damage to the healthy tissues. It then introduces the concept of nanotechnology as a means that overcome these limitations. Utilizing nanoparticles as means of administration for anticancer agents is a key aspect of targeted therapy. Nanoparticles can be engineered to possess specific characteristics, size, shape, surface charge, and functionalization are a few characteristics, which allow them to selectively target cancer cells sparing healthy tissues. Various types of nanoparticles, including liposomes, polymeric nanoparticles, and metallic nanoparticles are discussed in relation due of their special characteristics and applications in cancer targeted therapy. This abstract delves into the strategies employed for targeted drug delivery using nanotechnology. Active target selection and passively targeting targets using enhanced permeability and retention (EPR) are two of these techniques, impact using ligands or antibodies, and stimuli-responsive mechanisms that disperse medication in response to particular conditions within the tumor microenvironment. The abstract additionally explores the role of nanotechnology in imaging and diagnostics for cancer detection and monitoring. Nanoparticles can serve as contrast agents for several imaging modalities, similar to MRI (magnetic resonance imaging) and CT (computed tomography), and others and emission based imaging example PET (positron emission tomography), enabling early and accurate diagnosis, as well as real-time monitoring of treatment response.

Keywords : Nanoparticles, Nano Medicine, Drug Delivery, Cancer Therapy.

References :

1. R. L. Siegel, K. D. Miller, and A. Jemal, "Cancer statistics, 2020," CA: A Cancer J. Clin., vol. 70, no. 1, pp. 7-30, Jan. 2020. DOI: https://doi.org/10.3322/caac.21590
2. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation," Cell, vol. 144, no. 5, pp. 646-674, Mar. 2011. DOI: https://doi.org/10.1016/j.cell.2011.02.013
3. B. Vogelstein et al., "Cancer genome landscapes," Science, vol. 339, no. 6127, pp. 1546-1558, Mar. 2013. DOI: https://doi.org/10.1126/science.1235122
4. J. A. Joyce and D. T. Fearon, "T cell exclusion, immune privilege, and the tumor microenvironment," Science, vol. 348, no. 6230, pp. 74-80, Apr. 2015. DOI: https://doi.org/10.1126/science.aaa6204
5. O. C. Farokhzad and R. Langer, "Impact of nanotechnology on drug delivery," ACS Nano, vol. 3, no. 1, pp. 16-20, Jan. 2009. DOI: https://doi.org/10.1021/nn900002m
6. Y. Matsumura and H. Maeda, "A new concept for macromolecular therapeutics in tumor targeted solid tumor therapy: mechanism of tumor-tropic accumulation of proteins and the antitumor agent smancs," Cancer Res., vol. 46, no. 12, pp. 6387-6392, Dec. 1986. DOI: https://doi.org/10.1007/BF02996366
7. H. Maeda, "The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting," Adv. Enzyme Regul., vol. 41, pp. 189-207, 2001. DOI: https://doi.org/10.1016/s0065-2571(00)00013-3
8. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O. C. Farokhzad, "Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology," Adv. Drug Deliv. Rev., vol. 66, pp. 2-25, Feb. 2014. DOI: https://doi.org/10.1016/j.addr.2013.11.009
9. D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and R. Langer, "Nanocarriers as an emerging platform for cancer therapy," Nat. Nanotechnol., vol. 2, no. 12, pp. 751-760, Dec. 2007. DOI: https://doi.org/10.1038/nnano.2007.387
10. S. K. Nune, P. Gunda, P. K. Thallapally, Y.-Y. Lin, M. L. Forrest, and C. J. Berkland, "Nanoparticles for biomedical imaging," Expert Opin. Drug Deliv., vol. 6, no. 11, pp. 1175-1194, Nov. 2009. DOI: https://doi.org/10.1517/17425240903229031
11. J. D. Byrne, T. Betancourt, and L. Brannon-Peppas, "Active targeting schemes for nanoparticle systems in cancer therapeutics," Adv. Drug Deliv. Rev., vol. 60, no. 15, pp. 1615-1626, Dec. 2008. DOI: https://doi.org/10.1016/j.addr.2008.08.005
12. R. Bazak, M. Houri, S. El Achy, S. Kamel, and T. Refaat, "Cancer active targeting by nanoparticles: a comprehensive review of literature," J. Cancer Res. Clin. Oncol., vol. 141, no. 5, pp. 769-784, May 2015. DOI: https://doi.org/10.1007/s0432-014-1767-3
13. E. Blanco, H. Shen, and M. Ferrari, "Principles of nanoparticle design for overcoming biological barriers to drug delivery," Nat. Biotechnol., vol. 33, no. 9, pp. 941-951, Sep. 2015. DOI: https://doi.org/10.1038/nbt.3330
14. V. V. Mody, R. Siwale, A. Singh, and H. R. Mody, "Introduction to metallic nanoparticles," J. Pharm. Bioallied Sci., vol. 2, no. 4, pp. 282-289, Oct. 2010. DOI: https://doi.org/10.4103/0975-7406.68499
15. S. Iravani, "Green synthesis of metal nanoparticles using plants," Green Chem., vol. 13, no. 10, pp. 2638-2650, 2011. DOI: https://doi.org/10.1039/C1GC15386B
16. K. S. Soppimath, T. M. Aminabhavi, A. R. Kulkarni, and W. E. Rudzinski, "Biodegradable polymeric nanoparticles as drug delivery devices," J. Control. Release, vol. 70, no. 1-2, pp. 1-20, Jan. 2001. DOI: https://doi.org/10.1016/S0168-3659(00)00339-4
17. N. Kamaly, B. Yameen, J. Wu, and O. C. Farokhzad, "Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release," Chem. Rev., vol. 116, no. 4, pp. 2602-2663, Feb. 2016. DOI: https://doi.org/10.1021/acs.chemrev.5b00346
18. A. Crintea et al., "Dendrimers: Advancements and Potential Applications in Cancer Diagnosis and Treatment—An Overview," Pharmaceutics, vol. 15, no. 5, p. 1406, May 2023. DOI: https://doi.org/10.3390/pharmaceutics15051406
19. U. Boas and P. M. Heegaard, "Dendrimers in drug research," Chem. Soc. Rev., vol. 33, no. 1, pp. 43-63, Jan. 2004. DOI: https://doi.org/10.1039/B309043B
20. A. M. Wu and P. D. Senter, "Arming antibodies: prospects and challenges for immunoconjugates," Nat. Biotechnol., vol. 23, no. 9, pp. 1137-1146, Sep. 2005. DOI: https://doi.org/10.1038/nbt1141
21. J. M. Reichert, C. J. Rosensweig, L. B. Fenge, and W. E. Pierce, "Monoclonal antibody successes in the clinic," Nat. Biotechnol., vol. 23, no. 9, pp. 1073-1078, Sep. 2005. DOI: https://doi.org/10.1038/nbt0905-1073
22. T. M. Allen and P. R. Cullis, "Liposomal drug delivery systems: from concept to clinical applications," Adv. Drug Deliv. Rev., vol. 65, no. 1, pp. 36-48, Jan. 2013. DOI: https://doi.org/10.1016/j.addr.2012.09.037
23. M. D. Fulton and W. Najahi-Missaoui, "Liposomes in Cancer Therapy: How Did We Start and Where Are We Now," Int. J. Mol. Sci., vol. 24, no. 7, p. 6615, Apr. 2023. DOI: https://doi.org/10.3390/ijms24076615
24. W. J. Stark, "Nanoparticles in biological systems," Angew. Chem. Int. Ed., vol. 50, no. 6, pp. 1242-1258, Feb. 2011. DOI: https://doi.org/10.1002/anie.200906684
25. L. Zhang, F. X. Gu, J. M. Chan, A. Z. Wang, R. S. Langer, and O. C. Farokhzad, "Nanoparticles in medicine: therapeutic applications and developments," Clin. Pharmacol. Ther., vol. 83, no. 5, pp. 761-769, May 2008. DOI: https://doi.org/10.1038/sj.clpt.6100400
26. H. Wang, K. Zhuang, and B. S. Leong, "Carbon nanomaterials for biological imaging and nanomedicinal therapy," Chem. Rev., vol. 113, no. 5, pp. 3407-3424, May 2013. DOI: https://doi.org/10.1021/cr300307s
27. Z. Liu, J. T. Robinson, S. M. Tabakman, K. Chen, and H. Dai, "Carbon materials for drug delivery & cancer therapy," Mater. Today, vol. 14, no. 7-8, pp. 316-323, Jul. 2011. DOI: https://doi.org/10.1016/S1369-7021(11)70161-4
28. I. L. Medintz, H. T. Uyeda, E. R. Goldman, and H. Mattoussi, "Quantum dot bioconjugates for imaging, labelling and sensing," Nat. Mater., vol. 4, no. 6, pp. 435-446, Jun. 2005. DOI: https://doi.org/10.1038/nmat1390
29. A. M. Smith, X. Gao, and S. Nie, "Quantum dot nanocrystals for in vivo imaging and cancer molecular detection," Photochem. Photobiol., vol. 80, no. 3, pp. 377-385, Nov. 2004. DOI: https://doi.org/10.1111/j.1751-1097.2004.tb00096.x
30. Q. A. Pankhurst, J. Connolly, S. K. Jones, and J. Dobson, "Applications of magnetic nanoparticles in biomedicine," J. Phys. D: Appl. Phys., vol. 36, no. 13, pp. R167-R181, Jun. 2003. DOI: https://doi.org/10.1088/0022-3727/36/13/201
31. A. K. Gupta and M. Gupta, "Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications," Biomaterials, vol. 26, no. 18, pp. 3995-4021, Jun. 2005. DOI: https://doi.org/10.1016/j.biomaterials.2005.02.009
32. S. V. Dorozhkin, "Calcium orthophosphates in nature, biology and medicine," Materials, vol. 2, no. 2, pp. 399-498, Apr. 2009. DOI: https://doi.org/10.3390/ma2020399
33. M. Epple et al., "Application of calcium phosphate nanoparticles in biomedicine," J. Mater. Chem., vol. 20, no. 1, pp. 18-23, 2010. DOI: https://doi.org/10.1039/B910885H
34. M. M. Gottesman, "Mechanisms of cancer drug resistance," Annu. Rev. Med., vol. 53, pp. 615-627, 2002. DOI: https://doi.org/10.1146/annurev.med.53.082901.103929
35. G. Szakács, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe, and M. M. Gottesman, "Targeting multidrug resistance in cancer," Nat. Rev. Drug Discov., vol. 5, no. 3, pp. 219-234, Mar. 2006. DOI: https://doi.org/10.1038/nrd1984
36. R. S. Wong, "Apoptosis in cancer: from pathogenesis to treatment," J. Exp. Clin. Cancer Res., vol. 30, no. 1, p. 87, Sep. 2011. DOI: https://doi.org/10.1186/1756-9966-30-87
37. A. L. Harris, "Hypoxia—a key regulatory factor in tumour growth," Nat. Rev. Cancer, vol. 2, no. 1, pp. 38-47, Jan. 2002. DOI: https://doi.org/10.1038/nrc704
38. M. W. Dewhirst, Y. Cao, and B. Moeller, "Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response," Nat. Rev. Cancer, vol. 8, no. 6, pp. 425-437, Jun. 2008. DOI: https://doi.org/10.1038/nrc2397
39. G. L. Semenza, "Hypoxia-inducible factors in physiology and medicine," Cell, vol. 148, no. 3, pp. 399-408, Feb. 2012. DOI: https://doi.org/10.1016/j.cell.2012.01.021
40. P. Carmeliet and R. K. Jain, "Angiogenesis in cancer and other diseases," Nature, vol. 407, no. 6801, pp. 249-257, Sep. 2000. DOI: https://doi.org/10.1038/35025220
41. D. Liang, G. H. Miller, and G. K. Tranmer, "Hypoxia Activated Prodrugs: Factors Influencing Design and Development," Curr. Med. Chem., vol. 22, no. 37, pp. 4313-4325, 2015. DOI: https://doi.org/10.2174/0929867322666151021111016
42. N. Baran and M. Konopleva, "Molecular Pathways: Hypoxia-Activated Prodrugs in Cancer Therapy," Clin. Cancer Res., vol. 23, no. 10, pp. 2382-2390, May 2017. DOI: https://doi.org/10.1158/1078-0432.CCR-16-0895
43. J. M. Brown and W. R. Wilson, "Exploiting tumour hypoxia in cancer treatment," Nat. Rev. Cancer, vol. 4, no. 6, pp. 437-447, Jun. 2004. DOI: https://doi.org/10.1038/nrc1367
44. C. P. Guise et al., "Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia," Chin. J. Cancer, vol. 33, no. 2, pp. 80-86, Feb. 2014. DOI: https://doi.org/10.5732/cjc.012.10205
45. J. Shi, P. W. Kantoff, R. Wooster, and O. C. Farokhzad, "Cancer nanomedicine: progress, challenges and opportunities," Nat. Rev. Cancer, vol. 17, no. 1, pp. 20-37, Jan. 2017. DOI: https://doi.org/10.1038/nrc.2016.108
46. S. R. D'Mello, C. N. Cruz, A. Q. Chen, M. Kapoor, S. L. Lee, and A. S. Woods, "The evolving landscape of drug products containing nanomaterials in the United States," Nat. Nanotechnol., vol. 12, no. 6, pp. 523-529, Jun. 2017. DOI: https://doi.org/10.1038/nnano.2017.67
47. S. Mura, J. Nicolas, and P. Couvreur, "Stimuli-responsive nanocarriers for drug delivery," Nat. Mater., vol. 12, no. 11, pp. 991-1003, Nov. 2013. DOI: https://doi.org/10.1038/nmat3776
48. R. A. Petros and J. M. DeSimone, "Strategies in the design of nanoparticles for therapeutic applications," Nat. Rev. Drug Discov., vol. 9, no. 8, pp. 615-627, Aug. 2010. DOI: https://doi.org/10.1038/nrd2591
49. T. M. Allen and P. R. Cullis, "Drug delivery systems: entering the mainstream," Science, vol. 303, no. 5665, pp. 1818-1822, Mar. 2004. DOI: https://doi.org/10.1126/science.1095833
50. M. El-Sayed and A. S. Hoffman, "The use of smart polymers in delivering drugs," Expert Opin. Biol. Ther., vol. 5, no. 1, pp. 23-32, Jan. 2005. DOI: https://doi.org/10.1517/14712598.5.1.23
51. Y. Yao et al., "Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance," Front. Mol. Biosci., vol. 7, p. 193, Sep. 2020. DOI: https://doi.org/10.3389/fmolb.2020.00193
52. K. M. L. Taylor-Pashow, J. Della Rocca, Z. Xie, S. Tran, and W. Lin, "Postsynthetic modifications of iron-carboxylate nanoscale metal-organic frameworks for imaging and drug delivery," J. Am. Chem. Soc., vol. 131, no. 40, pp. 14261-14263, Oct. 2009. DOI: https://doi.org/10.1021/ja906198y
53. C. H. Choi et al., "Multimodal imaging and therapy of cancer with nanoscale particles," Expert Opin. Drug Deliv., vol. 9, no. 7, pp. 781-797, Jul. 2012. DOI: https://doi.org/10.1517/17425240.2012.688053
54. S. K. Nune et al., "Nanoparticles for biomedical imaging," Expert Opin. Drug Deliv., vol. 6, no. 11, pp. 1175-1194, Nov. 2009. DOI: https://doi.org/10.1517/17425240903229031
55. C. M. Hu, L. Zhang, S. Aryal, C. Cheung, R. H. Fang, and L. Zhang, "Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform," Proc. Natl. Acad. Sci. U.S.A., vol. 108, no. 27, pp. 10980-10985, Jul. 2011. DOI: https://doi.org/10.1073/pnas.1106634108
56. Y. Zhang, M. R. K. Ali, E. Oyelere, B. Hondroulis, and M. A. El-Sayed, "Multiplexing therapeutics for the treatment of cancer," Bioconjug. Chem., vol. 27, no. 1, pp. 1-13, Jan. 2016. DOI: https://doi.org/10.1021/acs.bioconjchem.5b00424
57. A. Z. Wang, R. Langer, and O. C. Farokhzad, "Nanoparticle delivery of cancer drugs," Annu. Rev. Med., vol. 63, pp. 185-198, Feb. 2012. DOI: https://doi.org/10.1146/annurev-med-040210-162544
58. S. S. Kelkar and T. M. Reineke, "Theranostics: combining imaging and therapy," Biomacromolecules, vol. 12, no. 6, pp. 187-200, Jun. 2011. DOI: https://doi.org/10.1021/bm2004068
59. D. T. Wiley, P. Webster, A. Gale, and M. E. Davis, "Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor," Proc. Natl. Acad. Sci. U.S.A., vol. 110, no. 21, pp. 8662-8667, May 2013. DOI: https://doi.org/10.1073/pnas.1307152110
60. A. M. Gobin, M. H. Lee, N. J. Halas, W. D. James, R. A. Drezek, and J. L. West, "Near-infrared resonant nanoshells for combined optical imaging and photothermal cancer therapy," Nano Lett., vol. 7, no. 7, pp. 1929-1934, Jul. 2007. DOI: https://doi.org/10.1021/nl070610y
61. G. Oberdörster, E. Oberdörster, and J. Oberdörster, "Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles," Environ. Health Perspect., vol. 113, no. 7, pp. 823-839, Jul. 2005. DOI: https://doi.org/10.1289/ehp.7339
62. A. Nel, T. Xia, L. Mädler, and N. Li, "Toxic potential of materials at the nanolevel," Science, vol. 311, no. 5761, pp. 622-627, Feb. 2006. DOI: https://doi.org/10.1126/science.1114397
63. V. P. Torchilin, "Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery," Nat. Rev. Drug Discov., vol. 13, no. 11, pp. 813-827, Nov. 2014. DOI: https://doi.org/10.1038/nrd4333
64. S. H. Bawa, P. F. Bawa, W. E. Maude, and A. Bawa, "Regulatory hurdles in clinical translation of nanomedicine," J. Control. Release, vol. 125, no. 3, pp. 165-171, Feb. 2008. DOI: https://doi.org/10.1016/j.jconrel.2007.10.024
65. J. Hrkach et al., "Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile," Sci. Transl. Med., vol. 4, no. 128, p. 128ra39, Apr. 2012. DOI: https://doi.org/10.1126/scitranslmed.3003651
66. W. H. De Jong and P. J. Borm, "Drug delivery and nanoparticles: applications and hazards," Int. J. Nanomedicine, vol. 3, no. 2, pp. 133-149, 2008. DOI: https://doi.org/10.2147/ijn.s596
67. S. Mitragotri, P. A. Burke, and S. MacMillan, "Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies," Nat. Rev. Drug Discov., vol. 13, no. 9, pp. 655-672, Sep. 2014. DOI: https://doi.org/10.1038/nrd4363
68. P. J. G. Gout et al., "Nanocarriers for cancer therapy: pharmacokinetic and biodistribution perspectives," J. Pharm. Sci., vol. 101, no. 3, pp. 860-880, Mar. 2012. DOI: https://doi.org/10.1002/jps.22851
69. E. Ruoslahti, S. N. Bhatia, and M. J. Sailor, "Targeting of drugs and nanoparticles to tumors," J. Cell Biol., vol. 188, no. 6, pp. 759-768, Mar. 2010. DOI: https://doi.org/10.1083/jcb.200910104
70. V. P. Torchilin, "Targeted pharmaceutical nanocarriers for cancer therapy and imaging," AAPS J., vol. 9, no. 2, pp. E128-E147, May 2007. DOI: https://doi.org/10.1208/aapsj0902015
71. M. A. Dobrovolskaia and S. E. McNeil, "Immunological properties of engineered nanomaterials," Nat. Nanotechnol., vol. 2, no. 8, pp. 469-478, Aug. 2007. DOI: https://doi.org/10.1038/nnano.2007.223
72. S. E. A. Gratton et al., "The effect of particle design on cellular internalization pathways," Proc. Natl. Acad. Sci. U.S.A., vol. 105, no. 33, pp. 11613-11618, Aug. 2008. DOI: https://doi.org/10.1073/pnas.0801763105